Due to the low number of patients expressing SCINDERIN, we combined the EPHRIN-A1 and SCINDERIN expression to address whether the presence of either SCINDERIN or EPHRIN-A1, possible surrogate markers of resistance of tumor cells to lysis mediated by CD8+ T cells, could influence the impact of CD8+ T cell on the clinical outcome of patients. The gene discussed is SCIN; the disease is neoplasm.